Cristian Alfredo Segura-Cerda

Dr. Cristian Alfredo Segura-Cerda

Secretaría de Ciencia, Humanidades, Tecnología e Innovación (Secihti), Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 October 2019 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
PDF file
Cristian Alfredo Segura-CerdaCristian Alfredo Segura-Cerda
Cristian Alfredo Segura-Cerda
WLWendy López-Romero
Wendy López-Romero
MFMario Alberto Flores-Valdez
Mario Alberto Flores-Valdez
Tuberculosis (TB) remains as the first cause of death among infectious diseases worldwide. Global incidence of tuberculosis is in part coincident with incidence of type 2 diabetes (T2D). Incidence of T2D is recognized as a high-risk factor that may contribute to tuberculosis dissemination. However, mechanisms which favor infection under T2D are just starting to emerge. Here, we first discuss the evidences that are available to support a metabolic connection between TB and T2D. Then, we analyze the evidences of metabolic changes which occur during T2D gathered thus far for its influence on susceptibility to M. tuberculosis infection and TB progression, such as hyperglycemia, increase of 1AC levels, increase of triglycerides levels, reduction of HDL-cholesterol levels, increased concentration of lipoproteins, and modification of the activity of some hormones related to the control of metabolic homeostasis. Finally, we recognize possible advantages of metabolic management of immunity to develop new strategies for treatment, diagnosis, and prevention of tuberculosis.

22 September 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KKKee Woong Kwon
Kee Woong Kwon
MAMichel de Jesús Aceves-Sánchez
Michel de Jesús Aceves-Sánchez
Cristian Alfredo Segura-CerdaCristian Alfredo Segura-Cerda
Cristian Alfredo Segura-Cerda
ECEunsol Choi
Eunsol Choi
HBHelle Bielefeldt-Ohmann
Helle Bielefeldt-Ohmann
MFMario Alberto Flores-Valdez
Mario Alberto Flores-Valdez
Previously, we reported that a hygromycin resistant version of the BCGΔBCG1419c vaccine candidate reduced tuberculosis (TB) disease in BALB/c, C57BL/6, and B6D2F1 mice infected with Mycobacterium tuberculosis (Mtb) H37Rv. Here, the second-generation version of BCGΔBCG1419c (based on BCG Pasteur ATCC 35734, without antibiotic resistance markers, and a complete deletion of BCG1419c) was compared to its parental BCG for immunogenicity and protective efficacy against the Mtb clinical isolate M2 in C57BL/6 mice. Both BCG and BCGΔBCG1419c induced production of IFN-γ, TNF-α, and/or IL-2 by effector memory (CD44+CD62L−), PPD-specific, CD4+ T cells, and only BCGΔBCG1419c increased effector memory, PPD-specific CD8+ T cell responses in the lungs and spleens compared with unvaccinated mice before challenge. BCGΔBCG1419c increased levels of central memory (CD62L+CD44+) T CD4+ and CD8+ cells compared to those of BCG-vaccinated mice. Both BCG strains elicited Th1-biased antigen-specific polyfunctional effector memory CD4+/CD8+ T cell responses at 10 weeks post-infection, and both vaccines controlled Mtb M2 growth in the lung and spleen. Only BCGΔBCG1419c significantly ameliorated pulmonary inflammation and decreased neutrophil infiltration into the lung compared to BCG-vaccinated and unvaccinated mice. Both BCG strains reduced pulmonary TNF-α, IFN-γ, and IL-10 levels. Taken together, BCGΔBCG1419c increased memory CD8+T cell-associated immunogenicity and mitigated pulmonary inflammation compared with BCG.

1 April 2018 in Vaccine
Verified
Journal Article
Closed access
Cristian Alfredo Segura-CerdaCristian Alfredo Segura-Cerda
Cristian Alfredo Segura-Cerda
MAMichel de Jesús Aceves-Sánchez
Michel de Jesús Aceves-Sánchez
BMBrenda Marquina-Castillo
Brenda Marquina-Castillo
DMDulce Mata-Espinoza
Dulce Mata-Espinoza
JBJorge Barrios-Payán
Jorge Barrios-Payán
MFMario Alberto Flores-Valdez
Mario Alberto Flores-Valdez

12 March 2020 in npj Vaccines
Verified
Journal Article
Open access
PDF file
Cristian Alfredo Segura-CerdaCristian Alfredo Segura-Cerda
Cristian Alfredo Segura-Cerda
BMBrenda Marquina-Castillo
Brenda Marquina-Castillo
VLVasti Lozano-Ordaz
Vasti Lozano-Ordaz
DMDulce Mata-Espinosa
Dulce Mata-Espinosa
JBJorge Alberto Barrios-Payán
Jorge Alberto Barrios-Payán
MFMario Alberto Flores-Valdez
Mario Alberto Flores-Valdez
Comorbidity between Tuberculosis (TB) and type 2 diabetes (T2D) is one of the greatest contributors to the spread ofMycobacterium tuberculosis (M. tuberculosis)in low- and middle-income countries. T2D compromises key steps of immune responses againstM. tuberculosisand it might affect the protection afforded by vaccine candidates against TB. We compared the protection and immune response afforded by the BCGΔBCG1419c vaccine candidate versus that of wild-type BCG in mice with T2D. Vaccination with both BCGΔBCG1419c, BCG or infection withM. tuberculosisreduced weight loss, hyperglycemia, and insulin resistance during T2D progression, suggesting that metabolic changes affecting these parameters were affected by mycobacteria. For control of acute TB, and compared with non-vaccinated controls, BCG showed a dominant T CD4+response whereas BCGΔBCG1419c showed a dominant T CD8+/B lymphocyte response. Moreover, BCG maintained an increased response in lung cells via IFN-γ, TNF-α, and IL-4, while BCGΔBCG1419c increased IFN-γ but reduced IL-4 production. As for chronic TB, and compared with non-vaccinated controls, both BCG strains had a predominant presence of T CD4+lymphocytes. In counterpart, BCGΔBCG1419c led to increased presence of dendritic cells and an increased production of IL-1 β. Overall, while BCG effectively reduced pneumonia in acute infection, it failed to reduce it in chronic infection, whereas we hypothesize that increased production of IL-1 β induced by BCGΔBCG1419c contributed to reduced pneumonia and alveolitis in chronic TB. Our results show that BCG and BCGΔBCG1419c protect T2D mice against TB via different participation of T and B lymphocytes, dendritic cells, and pro-inflammatory cytokines.

8 May 2023 in Vaccine
Verified
Journal Article
Closed access
MAMichel de Jesús Aceves-Sánchez
Michel de Jesús Aceves-Sánchez
JBJorge Alberto Barrios-Payán
Jorge Alberto Barrios-Payán
Cristian Alfredo Segura-CerdaCristian Alfredo Segura-Cerda
Cristian Alfredo Segura-Cerda
MFMario Alberto Flores-Valdez
Mario Alberto Flores-Valdez
DMDulce Mata-Espinosa
Dulce Mata-Espinosa
Rogelio Hernández-PandoRogelio Hernández-Pando
Rogelio Hernández-Pando

1 May 2018 in Molecular Immunology
Verified
Journal Article
Closed access
MFMario Alberto Flores-Valdez
Mario Alberto Flores-Valdez
Cristian Alfredo Segura-CerdaCristian Alfredo Segura-Cerda
Cristian Alfredo Segura-Cerda
JGJorge Gaona-Bernal
Jorge Gaona-Bernal